Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma

Hematology/Oncology Clinics of North America

Volumn 31, Issue 3, 2017, Pages 529-544

  Anandappa, Gayathri ^a,b   Chau, Ian ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

AZD4547; Claudin inhibitors; FGFR2 inhibitors; Gastric adenocarcinoma; Gastroesophageal adenocarcinoma; MMP inhibitors; Napabucasin; STAT3 inhibitors

Indexed keywords

ANDECALIXIMAB; ANTINEOPLASTIC AGENT; AZD 4547; CAPECITABINE; CETUXIMAB; DOCETAXEL; DOVITINIB; EPIRUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IMAB362; IPILIMUMAB; IRINOTECAN; LUCITINIB; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NAPABUCASIN; NIVOLUMAB; OPB 31121; OPB 51602; OXALIPLATIN; PACLITAXEL; PEMBROLIZUMAB; PONATINIB; REGORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; CLAUDIN; FGFR2 PROTEIN, HUMAN; GELATINASE; TUMOR PROTEIN;

ABDOMINAL CRAMP; ADVANCED CANCER; ANOREXIA; AUTOPHOSPHORYLATION; CANCER PROGNOSIS; CANCER STEM CELL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; VOMITING; WEAKNESS; X-RAY COMPUTED TOMOGRAPHY; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; ESOPHAGEAL NEOPLASMS; GENETICS; METABOLISM; PATHOLOGY; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLAUDINS; ESOPHAGEAL NEOPLASMS; GELATINASES; GENE AMPLIFICATION; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS;

EID: 85015775820     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2017.02.001     Document Type: Review

References (37)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:5 (2015), E359–E386.
2. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
3. Jang, J.H., Shin, K.H., Park, J.G., Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61:9 (2001), 3541–3543.
4. Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61:2 (2011), 69–90.
5. Turner, N., Grose, R., Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:2 (2010), 116–129.
6. Hattori, Y., Itoh, H., Uchino, S., et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2:8 (1996), 1373–1381.
7. Matsumoto, K., Arao, T., Hamaguchi, T., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106:4 (2012), 727–732.
8. Pearson, A., Smyth, E., Babina, I.S., et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 6:8 (2016), 838–851.
9. Su, X., Zhan, P., Gavine, P.R., et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 110:4 (2014), 967–975.
10. Gavine, P.R., Mooney, L., Kilgour, E., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72:8 (2012), 2045–2056.
11. Xie, L., Su, X., Zhang, L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19:9 (2013), 2572–2583.
12. Bang, Y.-J., Van Cutsem, E., Mansoor, W., et al. A randomized, open-label phase II study of AZD4547 (AZD) versus paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. ASCO Meeting Abstracts, 33(15_Suppl), 2015, 4014.
13. Chang, J., Wang, S., Zhang, Z., et al. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget 6:4 (2015), 2009–2022.
14. Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:7517 (2014), 202–209.
15. Piro, G., Carbone, C., Cataldo, I., et al. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. Clin Cancer Res 22:24 (2016), 6164–6175.
16. Cafferkey, C., Chau, I., Novel STAT 3 inhibitors for treating gastric cancer. Expert Opin Investig Drugs 25:9 (2016), 1023–1031.
17. Lee, J., Kang, W.K., Park, J.O., et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 117:8 (2009), 598–606.
18. Deng, J.Y., Sun, D., Liu, X.Y., et al. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 16:42 (2010), 5380–5387.
19. Li, Y., Rogoff, H.A., Keates, S., et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A 112:6 (2015), 1839–1844.
20. Ernst, M., Najdovska, M., Grail, D., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118:5 (2008), 1727–1738.
21. Yang, Z., Guo, L., Liu, D., et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 6:7 (2015), 5072–5087.
22. Bendell, J.C., Hong, D.S., Burris, H.A. 3rd, et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 74:1 (2014), 125–130.
23. Wong, A.L., Soo, R.A., Tan, D.S., et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol 26:5 (2015), 998–1005.
24. Langleben, A., Supko, J.G., Hotte, S.J., et al. A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. ASCO Meeting Abstracts, 31(15_Suppl), 2013, 2542.
25. Jonker, D.J., Stephenson, J., Edenfield, W.J., et al. A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts, 32(15_Suppl), 2014, 2546.
26. Hitron, M., Stephenson, J., Chi, K.N., et al. A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies. ASCO Meeting Abstracts, 32(15_Suppl), 2014, 2530.
27. Shah, M.A., Muro, K., Shitara, K., et al. The BRIGHTER trial: a phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma. ASCO Meeting Abstracts, 33(15_Suppl), 2015, TPS4139.
28. Soini, Y., Tommola, S., Helin, H., et al. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch 448:1 (2006), 52–58.
29. Jun, K.H., Kim, J.H., Jung, J.H., et al. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int J Surg 12:2 (2014), 156–162.
30. Rogers, L.M., Veeramani, S., Weiner, G.J., Complement in monoclonal antibody therapy of cancer. Immunol Res 59:1–3 (2014), 203–210.
31. Al-Batran, S.-E., Schuler, M.H., Zvirbule, Z., et al. FAST: an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. ASCO Meeting Abstracts, 34(15_Suppl), 2016, LBA4001.
32. Bergers, G., Brekken, R., McMahon, G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:10 (2000), 737–744.
33. Marshall, D.C., Lyman, S.K., McCauley, S., et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS One, 10(5), 2015, e0127063.
34. Tierney, G.M., Griffin, N.R., Stuart, R.C., et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 35:4 (1999), 563–568.
35. Bramhall, S.R., Hallissey, M.T., Whiting, J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86:12 (2002), 1864–1870.
36. Bendell, J.C., Starodub, A., Shah, M.A., et al. Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors. ASCO Meeting Abstracts, 33(15_Suppl), 2015, 4030.
37. Shah, M.A., Starodub, A., Wainberg, Z.A., et al. Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric/GE junction tumors. ASCO Meeting Abstracts, 34(15_Suppl), 2016, 4033.